Search by conditions:

 

Protocol Description Phase
17-607 A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
16-456 A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination with Other Agents in Advanced Cancer  (View details on clinicaltrial.gov) Phase I
18-228 A Phase 1, Open-Label, Dose-Finding Study of ASN007 in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-288 A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult patients with advanced solid tumors  (View details on clinicaltrial.gov) Phase I
16-399 A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase II
18-638 A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation  (View details on clinicaltrial.gov) Phase II
18-424 A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Metastatic Colorectal Carcinoma  (View details on clinicaltrial.gov) Phase II
14-166 A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer  (View details on clinicaltrial.gov) Phase II
18-144 A Phase 2 Study of Dabrafenib and Trametinib in Combination with PDR001 in patients with BRAFV600E metastatic colorectal cancer  (View details on clinicaltrial.gov) Phase II
17-044 A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer  (View details on clinicaltrial.gov) Phase II
17-137 A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer.  (View details on clinicaltrial.gov) Phase I
18-626 A Phase I, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects with Advanced Solid Tumors with a Specific KRAS Mutation  (View details on clinicaltrial.gov) Phase II
18-289 A Phase I, First-in-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Daily for 21 Days to Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
18-274 A Phase II Study of M6620 (VX-970) in Selected Solid Tumors  (View details on clinicaltrial.gov) Phase II
16-193 A pilot study of Ga-68-DOTA-TOC imaging in participants with small bowel carcinoid tumors.  (View details on clinicaltrial.gov) N/A
18-441 An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas  (View details on clinicaltrial.gov) Phase I
17-251 An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-615 An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification  (View details on clinicaltrial.gov) Phase II
17-673 MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer  (View details on clinicaltrial.gov) Phase II
17-021 Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
17-380 Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase I
17-231 Phase Ib/II Study of TAS-102 plus radiation therapy for the treatment of the liver in patients with hepatic metastases from colorectal cancer  (View details on clinicaltrial.gov) Phase II
22 clinical trials listed

Back to Top